Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc. (FOXO) generates news across healthcare services, behavioral health, biospecimen sourcing and biotechnology. Company announcements describe operations at its critical access hospital in East Tennessee, its behavioral health subsidiary, Myrtle Recovery Centers, its biospecimen provider Vector BioSource, Inc., and its biotechnology arm, FOXO Labs, Inc.
News items for FOXO often cover developments at Big South Fork Medical Center, including service expansions such as swing bed and wound care services and agreements like its Performance Network Agreement with Covenant Health to provide swing bed services within a broader performance network. Updates may also highlight patient volumes, service mix and new clinical offerings at the hospital.
FOXO’s behavioral health subsidiary, Myrtle Recovery Centers, Inc., appears frequently in company communications through license renewals, operational updates, and recognition from local and statewide organizations. News has included approval to receive Scott County Opioid Abatement Funds to support care for uninsured patients, as well as acknowledgments from associations such as the Rural Health Association of Tennessee.
On the life sciences side, FOXO issues press releases about its acquisition and growth of Vector BioSource, Inc., an information, data and biospecimen sourcing provider serving biotechnology, clinical research and pharmaceutical research sectors. These updates detail acquisition terms, revenue run-rate information, and planned funding for Vector’s growth initiatives.
FOXO also publishes news about FOXO Labs, Inc. and its epigenetics business, including the decision to pursue a spin-off of FOXO Labs, descriptions of its patent related to DNA epigenetic data, and its work on epigenetic biomarkers and AI-based wellness coaching concepts.
Corporate-level news for FOXO includes reverse stock split actions, changes to authorized share capital, preferred stock designations, and listing status updates, such as the transition of its common stock trading from NYSE American to the OTC market. Investors and observers can use the FOXO news feed on Stock Titan to follow these healthcare, biotechnology and corporate governance developments as they are disclosed in press releases and related SEC filings.
FOXO Technologies Inc. (NYSE American: FOXO) has filed its Annual Report on Form 10-K for fiscal year 2024 on April 15, 2025. The company's independent auditors included a going concern explanatory paragraph in their audit opinion, indicating uncertainty about FOXO's ability to continue operations.
CEO Seamus Lagan characterized 2024 as a transition year, highlighting the completion of two strategic acquisitions: Myrtle Recovery Centers, Inc., a behavioral health business, and Rennova Community Health, Inc., which operates rural hospitals in Tennessee. Management expressed optimism about growth prospects from existing operations and potential acquisitions in 2025.
FOXO Technologies Inc. (NYSE American: FOXO) has signed a non-binding agreement to acquire Vector Biosource Inc., an information and biospecimen sourcing provider serving biotechnology and pharmaceutical research industries. Vector projects $800,000 in revenues for 2025 without additional capital.
The acquisition terms include:
- $750,000 in Series D Preferred Stock upfront
- Additional $750,000 in Series D Preferred Stock tied to 2025 revenue milestones
- Future earnout payments in Series D Preferred Stock based on 2026-2027 performance
The deal closing, expected within 45 days, is contingent on definitive agreements, due diligence, $1 million working capital provision, and other conditions. The acquisition aims to leverage Vector's healthcare sector position and growth potential through FOXO's corporate infrastructure and potential subsidiary synergies.
FOXO Technologies (NYSE American: FOXO) has reported positive developments at its behavioral health subsidiary, Myrtle Recovery Centers. The company's substance abuse treatment facility in Oneida, Tennessee has achieved stable operations, maintaining an occupancy rate of 75% or higher since early 2025, occasionally reaching full capacity.
Myrtle has successfully finalized several in-network contracts with major managed care organizations in 2025. The company will participate as a Silver Sponsor in the upcoming ETAADAC Conference in Knoxville, TN (March 19-21, 2025), an event gathering industry leaders to discuss addiction counseling and treatment developments.
FOXO Technologies (NYSE American: FOXO) has executed a non-binding acquisition agreement for two assisted living facilities in Florida for a total consideration of $60 million. The facilities comprise 129 and 137 units respectively, with each facility priced at $30 million including milestone-based payments.
The company aims to complete definitive agreements within 60 days, with closing expected 60-120 days thereafter, subject to due diligence and financing conditions. FOXO is considering funding through a new series of preferred stock listing. The company views these acquisitions as strategic entries into the healthcare sector's recurring revenue model, with milestone payments tied to facility revenue increases.
FOXO Technologies Inc. (NYSE American: FOXO) has provided a shareholder update outlining recent accomplishments and future strategy. The company has transformed from minimal revenues to acquiring businesses with potential for $20M+ annual profitable revenue. They've improved shareholders' equity by over $21M through debt-to-equity restructuring to meet NYSE American listing requirements.
FOXO operates three main businesses: FOXO Labs (epigenetics division with 13,000+ individual dataset), Myrtle Recovery Centers (30-bed behavioral health facility expecting $3-4M annual revenue), and Scott County Community Hospital (Big South Fork Medical Center). The company has converted approximately $6M of additional debt to equity through preferred stock issuance and is actively seeking healthcare sector acquisition opportunities.
Key priorities include growing rural hospital and behavioral health businesses, monetizing the epigenetics division, and potentially pursuing additional healthcare acquisitions. The company plans to update its web presence and complete various work steps within 30-60 days.
FOXO Technologies Inc. (NYSE American: FOXO) has announced its Special Meeting of Shareholders scheduled for January 17, 2025, at 10:30 am EST. The virtual meeting follows the Company's Definitive Proxy Statement filed with the SEC on January 6, 2025. Shareholders of record as of January 3, 2025, will be eligible to vote on the proposed approvals.
Shareholders can vote either online at www.cstproxyvote.com or by attending the virtual meeting at https://www.cstproxy.com/foxotechnologies/2025 using their 12-digit control number. The Board of Directors recommends voting in favor of the Proposals listed on the Proxy Card. CEO Seamus Lagan expressed that the meeting will fulfill obligations from recent acquisition agreements and highlighted the company's transformation in the second half of 2024 as a foundation for building significant shareholder value.
FOXO Technologies (NYSE American: FOXO) has announced a special virtual shareholders meeting scheduled for January 17, 2025, at 10:30 AM EST. The meeting's primary purpose is to seek approval for several proposals, with shareholders of record as of January 3, 2025, eligible to vote.
The main proposal requires shareholder approval for the issuance of Class A Common Stock exceeding 20% of outstanding shares upon conversion of Series A Preferred Stock, and voting terms that may constitute a 'Change of Control' under NYSE American Rules. Additional proposals include potential meeting adjournment if needed to gather more proxies.
CEO Seamus Lagan emphasized that following the meeting, the company plans to focus on growing revenues from existing operations and exploring acquisition opportunities to accelerate growth and increase shareholder value. A Definitive Proxy Statement with detailed information was filed with the SEC on January 6, 2025.
FOXO Technologies Inc. (NYSE American: FOXO) has announced its 2024 Annual General Meeting of Shareholders, scheduled for December 31, 2024, at 9:30 am CST. The meeting will be conducted virtually via live webcast, with shareholders of record as of December 19, 2024, eligible to vote. CEO Seamus Lagan highlighted that FOXO has resolved all NYSE American listing deficiencies and acquired significant revenue-generating businesses. The company plans to hold an additional Special Meeting for other matters requiring shareholder approval. Management expressed optimism about their acquisition and growth strategy for 2025 and beyond.
FOXO Technologies has announced regaining compliance with NYSE American listing requirements by achieving stockholders' equity greater than $4M. This marks a significant turnaround from the company's $17.5M stockholders' deficit reported in September 2024. The improvement was achieved through several key transactions, including:
- Rennova Health's exchange of $21M Senior Secured Note for 21,000 shares of Series A Preferred Stock
- An institutional investor's $1M funding and $2.2M Senior Notes exchange for 2,464 Series A Preferred shares
- Settlement with KR8 AI through 3,000 shares of Series D Preferred Stock
- Conversion of $1M in liabilities to approximately 2M shares of Class A Common Stock
FOXO Technologies (NYSE American: FOXO) has announced major restructuring and capital raising transactions aimed at improving its balance sheet and meeting NYSE American listing requirements. Key transactions include Rennova Health's exchange of approximately $21 million of Senior Secured Notes for 21,000 shares of Series A Preferred Stock, an institutional investor's $1.0 million funding and exchange of $2.2 million of Senior Notes for 2,464 Series A Preferred shares, and settlement of KR8 liabilities for 3,000 Series D Preferred shares.
The company has appointed Seamus Lagan as CEO, who brings over 30 years of experience in startups and distressed companies. These transactions have collectively reduced liabilities and increased stockholders' equity by $26.4 million, potentially eliminating the risk of NYSE American delisting.